1. Scrip
  2. >>Focus On Asia
  3. >>Japan

First Digital Therapeutic App Filed For Approval In Expanding Japan ADHD Market

 
• By Lisa Takagi

A pioneering approval filing for a therapeutic app by Shionogi is set to herald expansion of ADHD therapies beyond the pill in Japan, along with growth in the pediatric segment for the disorder.

Shionogi has been developing the Japanese version of Akili's AKL-T01 since signing the licensing deal in 2019.
Shionogi developing Japanese version of Akili's AKL-T01 since 2019 licensing deal • Source: Shutterstock

Shionogi & Co. Ltd. has filed for the first Japanese approval of a digital therapeutic app, for pediatric attention deficit hyperactivity disorder (ADHD), potentially providing a new treatment option beyond medications in the country's growing market for the disorder.

SDT-001 is a localized Japanese-language version of Akili Interactive Labs’s AKL-T01, which became the first digital app to treat...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

More from Focus On Asia